Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies

Review

(3109) Views  (1461) Full article downloads

Authors: Matthias Meier, Michael Hummel

Published Date October 2009 Volume 2009:5 Pages 859 - 871

DOI: http://dx.doi.org/10.2147/VHRM.S4808

Matthias Meier,^1,2 Michael Hummel^3,4

¹Clinic for Hypertension and Nephrology, Hannover, Germany; ²Department of Nephrology, Hannover Medical School, Hannover, Germany; ³Academic Hospital Schwabing, Munich, Germany; ⁴Diabetes Research Institute, Munich, Germany

Abstract: Type 2 diabetes mellitus (T2DM) is associated with a high risk of complications, essentially macrovascular events. Surprisingly, the effect of improved glucose control on coronary and cerebrovascular complications and the target level of glycated hemoglobin (HbA_1c) in this population remains questionable. We here report the results of 4 recently published randomized controlled trials (ACCORD, ADVANCE, VADT, UKPDS post-trial), which did not demonstrate a significant reduction of cardiovascular events in the intensive group compared to the standard group. On the contrary, in ACCORD, the study with the most ambitious goal (HbA_1c < 6%), the overall and cardiovascular mortality was greater in the intensive group, although the risk of microangiopathic complications, especially nephropathy, was significantly decreased. VADT suggests that one possibility for the lack of observed effect of intensive therapy could be that the cardiovascular benefit is delayed. This contrasts strongly with the long-term postintervention outcomes of UKPDS, which show a persistent benefit of glycemic control during 10 years of post-trial follow-up (‘legacy effect’). Therefore, the best way to protect patients with T2DM against coronary and cerebrovascular disease is to target all cardiovascular risk factors as early as possible by an individualized approach.

Keywords: glycemic control, cardiovascular, ACCORD, ADVANCE, VADT, UKPDS post-trial